Notably, five of the nine drugs predicted to interact with OCT3 at clinically relevant unbound concentrations have warnings and precautions related to cardiovascular side-effects (e.g. cardiac arrhythmia) (Table I, Table SII). The gene discussed is SLC22A3; the disease is cardiac arrhythmia.